Estimaciones de analistas de Wall Street para Mereo BioPharma Group plc (MREO): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 5 |
| Mantener | 3 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 8 |
| Calificación media (1-5) | 0.62 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.01 | ||
| 2026-08-11 | $-0.01 | $-0.01 | +0.0% |
| 2026-05-12 | $-0.01 | $0.02 | -150.0% |
| 2026-03-19 | $-0.01 | $-0.01 | +0.0% |
| 2025-11-10 | $-0.01 | $-0.01 | -20.0% |
| 2025-08-12 | $-0.02 | $-0.01 | -100.0% |
| 2025-05-13 | $-0.02 | $-0.01 | -100.0% |
| 2025-03-26 | $-0.01 | $-0.02 | +50.0% |
Ratios de valoración
| Precio / Valor contable | 1.44 |
| EV / EBITDA | -0.33 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | -$3.3M | 0 | 0 | 0 | $49.2M | 0 | $10.0M | 0 | $500000 |
| Coste de Ventas | $24.6M | $34.6M | $22.7M | $2.0M | $2.1M | $24.2M | -$1.1M | $2.6M | 0 | $133000 |
| Beneficio Bruto | -$24.6M | -$37.9M | -$22.7M | -$2.0M | -$2.1M | $25.0M | $1.1M | $7.4M | 0 | $367000 |
| I+D | $24.6M | $34.6M | $22.7M | $30.1M | $21.0M | $31.8M | $29.5M | $17.4M | 0 | $17.8M |
| Generales y Administrativos | $11.6M | $10.7M | $12.5M | $18.3M | $25.2M | $21.5M | $26.1M | $18.4M | 0 | $23.0M |
| Gastos Operativos | $11.6M | $10.7M | $12.5M | $48.4M | $46.1M | $53.3M | $55.6M | $35.8M | 0 | $38.6M |
| Beneficio Operativo | -$36.2M | -$45.3M | -$35.2M | -$50.4M | -$48.2M | -$28.3M | -$54.4M | -$28.4M | 0 | -$38.3M |
| EBITDA | -$38.4M | -$44.4M | -$34.9M | -$44.6M | -$203.4M | $25.5M | -$37.9M | -$26.1M | 0 | -$40.5M |
| Gastos por Intereses | $179765 | $1.1M | $2.4M | $3.5M | $6.4M | $5.2M | $4.2M | $2.9M | 0 | $255000 |
| Beneficio Antes de Impuestos | -$33.7M | -$47.0M | -$37.3M | -$52.5M | -$213.4M | $19.2M | -$42.9M | -$30.0M | 0 | -$41.9M |
| Impuestos | -$5.3M | -$8.2M | -$5.3M | -$8.0M | -$3.6M | $2.0M | -$718000 | -$532000 | 0 | 0 |
| Beneficio Neto | -$28.4M | -$38.8M | -$32.0M | -$44.5M | -$209.8M | $17.2M | -$42.2M | -$29.5M | 0 | -$41.9M |
| BPA | $-19553.91 | $-19003.80 | $-14352.87 | $-12902.58 | $-16503.30 | $749.65 | $-1.80 | $-1100.22 | $0.00 | $-0.26 |
| BPA Diluido | $-19553.91 | $-19003.80 | $-14352.87 | $-12902.58 | $-16503.30 | $749.65 | $-1.80 | $-1100.22 | $0.00 | $-0.26 |
| Acciones en Circulación (Diluidas) | $9.0M | $13.8M | $14.2M | $17.9M | $67.8M | $116.7M | $22.8M | $131.9M | 0 | $159.4M |
Precio
| Precio | $0.27 |
| Capitalización | $42M |
| Bolsa | NASDAQ |
| País | GB |
Empresas relacionadas: ACIU · ALDX · CADL · CAPR · CTNM · IMMP · KYTX
Explorar sector: Healthcare · Biotechnology
Más secciones de MREO: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones